PHILLIPSBURG, N.J., Oct. 21, 2013 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) announced today that data from two of its clinical programs, the Phase 1 dose-escalation CDX-1127 study and the Phase 2 recurrent rindopepimut study, will be presented at two upcoming medical meetings, the Society for Immunotherapy of Cancer (SITC) and the Society of Neuro-Oncology (SNO), respectively. The Company also announced its communication plan around these data presentations.
SITC, November 7-10, National Harbor, Maryland
The embargo for all data to be presented at SITC lifts on Thursday, November 7 at 8:00 am ET, at which time abstracts will be published on the SITC website. Celldex has three abstracts on CDX-1127 that have been accepted for poster presentation (outlined below). Concurrent with the embargo lifting, Celldex will issue a press release that will include the preliminary data contained in the abstracts and updated data that will be presented in the poster sessions. Management will also hold a conference call at 8:30 am ET on Thursday, November 7 to review the data.
-
Data from the solid tumor arm of the Phase 1 dose-escalation study of CDX-1127 will be presented in a poster session entitled "A Phase 1 Study of an Agonist anti-CD27 Human Antibody (CDX-1127) in Patients with Advanced Hematologic Malignancies or Solid Tumors" on Saturday, November 9 from 1:00 pm to 2:00 pm and 6:15 pm to 7:15 pm ET.
-
Data from the hematologic arm of the Phase 1 dose-escalation study of CDX-1127 will be presented in a poster session entitled "A Phase 1 Study of an Agonist anti-CD27 Human Antibody (CDX-1127) in Patients with Advanced Hematologic Malignancies or Solid Tumors" on Saturday, November 9 from 1:00 pm to 2:00 pm and 6:15 pm to 7:15 pm ET.
-
Data from preclinical combination studies of CDX-1127 with chemotherapies and checkpoint inhibitors will be presented in a poster session entitled "Combination Therapies Augment the Anti-tumor Activity of Agonist CD27 mAb in Human CD27 Transgenic Mouse Models" on Friday, November 8 from 1:00 pm to 2:00 pm and 6:15 pm to 7:15 pm ET.
SNO, November 21-24, San Francisco, California
The embargo for abstracts lifts on Monday, November 11 at 7:00 am ET, at which time the abstracts will be published on the SNO website. Preliminary data from the ReACT study will be included in an abstract accepted for an oral presentation entitled "ReACT: a Phase 2 Study of Rindopepimut Vaccine (CDX-110) Plus Bevacizumab in Relapsed Glioblastoma." Celldex will present a more expansive, updated data package from the ReACT study in this oral session, which is scheduled for Sunday, November 24 from 10:20 am to 12:00 pm PT. The Company will issue a press release in concordance with this presentation. On Monday, November 25 at 8:30 am ET, management will also hold a conference call to review the data.
About Celldex Therapeutics, Inc.:
Celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. Our pipeline is built from a proprietary portfolio of antibodies and immunomodulators used alone and in strategic combinations to create novel, disease-specific therapies that induce, enhance or suppress the body's immune response. Visit www.celldextherapeutics.com.
CONTACT: Company Contact:
Sarah Cavanaugh
Vice President of IR & Corp Comm
Celldex Therapeutics, Inc.
(781) 433-3161
scavanaugh@celldextherapeutics.com
